Bacterial toxin implicated In young adult colon cancers
A bacterial toxin called colibactin, produced by certain strains of E. coli, appears to alter gut DNA in a way that prompts colon cancer, researchers report in the journal Nature.
Colibactin leaves behind specific patterns of DNA mutations that are more than three times as common in early-onset colon cancers, specifically in adults younger than 40 compared to those 70 or older, results show.
Researchers suspect colibactin-producing bacteria may be silently colonizing children's colons, setting the stage for cancer in midlife and beyond.
"These mutation patterns are a kind of historical record in the genome, and they point to early-life exposure to colibactin as a driving force behind early-onset disease," senior researcher Ludmil Alexandrov said in a news release. He is a professor of bioengineering and cellular and molecular medicine at the University of California-San Diego.
Colon cancers have been steadily increasing among people under 50, so much so that guidelines have been updated to lower the age of screening to 45.
Colon cancer rates increased by 2.4% a year among people younger than 50 between 2012 and 2021, according to the American Cancer Society. Likewise, death rates in people under 55 have been increasing about 1% a year since the mid-2000s.
At the same time, colon cancers have been declining among older adults, thanks to screening methods like colonoscopy, the ACS says.
For the new study, researchers analyzed 981 colon cancer samples collected from patients in 11 countries.
The analysis revealed that colibactin is a common toxin among these cases, particularly in early-onset colon cancers.
The results show that colibactin's damaging effects begin early in tumor development, and account for about 15% of the earliest genetic alterations that directly promote cancer development.
"If someone acquires one of these driver mutations by the time they're 10 years old," Alexandrov explained, "they could be decades ahead of schedule for developing colorectal cancer, getting it at age 40 instead of 60."
More research now is needed to figure out how children are being exposed to colibactin-producing bacteria, and what can be done about it, researchers said.
The team also is working on an early detection test that could analyze stool samples for colobactin-related mutations.
"This reshapes how we think about cancer," Alexandrov said. "It might not be just about what happens in adulthood -- cancer could potentially be influenced by events in early life, perhaps even the first few years.
"Sustained investment in this type of research will be critical in the global effort to prevent and treat cancer before it's too late."
More information
The American Cancer Society has more on colon cancer rates.
Copyright © 2025 HealthDay. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
Alume Biosciences Announces Publication of Data Examining First-in-Human Use of Bevonescein to Illuminate Nerves in Nature Communications
SAN DIEGO, July 02, 2025--(BUSINESS WIRE)--Alume Biosciences, a late-clinical stage biotechnology company developing nerve-illuminating technology to enhance surgical safety, today announced the publication of first-in-human data from a Phase 1 clinical trial evaluating bevonescein (ALM-488) in head and neck surgeries. The original research article titled, "Intraoperative Nerve-Specific Fluorescence Imaging in Head and Neck Surgery: A Phase 1 Clinical Trial," authored by Lee, Y., Orosco, R., et al., was published in Nature Communications. Bevonescein is a novel fluorescent visualization drug designed to selectively illuminate nerves during surgery, helping to prevent inadvertent nerve injury and is currently being evaluated in ongoing Phase 3 clinical trials. "Currently, many head and neck surgeries result in nerve injuries, which can be catastrophic for the patients," said Eben L. Rosenthal, MD, Barry Baker Professor and Chair of the Department of Otolaryngology–Head and Neck Surgery at Vanderbilt University Medical Center and study senior author. "This first-in-human data demonstrate the safety of bevonescein and its potential to enhance nerve visualization in real time. It's especially promising to see improvements in nerve conspicuity at the optimal dose." Key Findings: Fluorescence Superiority: Bevonescein provided enhanced nerve visualization with higher nerve conspicuity scores in fluorescent compared to white light. All participants demonstrated improved visible nerve length; 57% showed more than 20% improvement. Optimal Dose Defined: The optimal treatment dose of bevonescein was 500mg. Favorable Safety Profile: No dose-limiting toxicities or infusion reactions occurred. No surgeries were delayed or canceled due to the study drug. "These data support our belief that bevonescein can help make surgery more precise by allowing surgeons to see nerves more clearly," said Quyen Nguyen, MD, PhD, Founder and CEO of Alume Biosciences. "When Roger Tsien and I started work on bevonescein, our vision was to translate his Nobel Prize-winning discoveries regarding fluorescence into tools that directly improve surgical outcomes. This milestone brings us closer to that goal." "With the growing adoption of fluorescence guidance in surgery, it's exciting to see this technology now applied to nerve identification," said Ryan Orosco, MD, Associate Professor, University of New Mexico and the study's co-lead author. "Bevonescein represents a paradigm shift in how we identify nerves during surgery, and ultimately how we improve patient outcomes." Study Overview The dose-defining and dose-timing clinical trial enrolled 27 adults undergoing elective head and neck surgery including parotidectomy, thyroidectomy and cervical neck dissections. Participants received intravenous bevonescein at varying doses to assess safety, pharmacokinetics, and optimal visualization timing. Surgical visualization of bevonescein-enabled nerve fluorescence was performed using the Zeiss Tivato surgical microscope with Yellow 560. Surgeons assessed nerve visualization using 4-point Likert scale that measured conspicuity, visible nerve length, and delineation of branching. About Bevonescein (ALM-488) Bevonescein is Alume's lead compound—a targeted fluorescent peptide-dye conjugate that binds to nerve tissue, enabling intraoperative nerve visualization. It is currently in Phase 3 clinical trials and is planned for New Drug Application (NDA) submission to the U.S. Food and Drug Administration in 2026. About Alume Biosciences Alume Biosciences is a biotechnology company pioneering nerve-targeted drugs to enhance surgical precision and preserve nerve function. Founded on a lead candidate co-invented by late Nobel Laureate Dr. Roger Tsien, Alume is committed to translating cutting-edge science into practical tools for surgeons and better outcomes for patients. Learn more at and LinkedIn. View source version on Contacts Media Contact Janine 201-245-6838 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
When is the next full 'buck moon'? What to know about celestial events in July
There are 12 full moons in 2025, and July will bring one that's called the 'Buck Moon.' A full moon occurs — simply put — when the Earth falls between the sun and the moon, which results in the visible portion of the moon being lit by the sun. If you're a regular sky gazer, keeping track of celestial movements, or just curious this month, here is what you need to know about upcoming lunar activity and other planetary sightings in July. The next Buck Moon will arrive on Thursday, July 10, and is expected to be at peak illumination at 4:37 p.m. Eastern time, according to The Old Farmer's Almanac. Derived from Indigenous American, European and colonial American influences, moon names signify a connection to the natural world. In July, as part of a yearly renewal process, male deer grow new antlers at peak capacity after having shed the old horns at the end of the rutting season — hence lending the name Buck Moon. Some other names for the July full moon are Thunder Moon, due to the thunderstorms, and Halfway Summer Moon. This moon is also called Berry Moon, Salmon Moon and Feather Moulting Moon. Middletown residents and others in the mid-Hudson Valley can spot the rise of the moon above the horizon at 8:58 p.m. by looking in the southeast direction. The moon will set at 4:50 a.m., southwestward. If you want to see surface details, you will need binoculars or a telescope. You can also use a digital camera. More: NYSEG seeks state approval for steep rate hikes for gas, electric customers Long-range forecast by Climate Prediction Center shows normal or leaning-above-normal temperatures and precipitation levels for July 9-15. If you are interested in locating other planets and constellations in the sky in July, here's what NASA recommends: Jupiter is expected in the second half of the month in the east during the hour before dawn — positioned low in the sky, rising higher each day. Mars is expected to appear all month in the west for a couple of hours, starting at the end of the twilight period — positioned approximately 20 degrees over the horizon line. Mercury makes a brief appearance in the first week of July in the western skies after dusk for up to 45 minutes — positioned 10 degrees above the horizon line or lower. Saturn will be visible all month at midnight — positioned rising high in the southern sky by sunrise. Venus will rise all month in early morning in the east in the hours before dawn. Aquila Constellation, the eagle-shaped cluster of stars, will appear all of July in the east in the first half of the night, anchored by its brightest star, Altair. This article originally appeared on Times Herald-Record: When to see the Buck Moon and other July events in mid-Hudson Valley
Scientific American
10 hours ago
- Scientific American
4,800-Year-Old Teeth Yield First Human Genome from Ancient Egypt
Teeth from an elderly man who lived around the time that the earliest pyramids were built have yielded the first full human genome sequence from ancient Egypt. The remains are 4,800 to 4,500 years old, overlapping with a period in Egyptian history known as the Old Kingdom or the Age of Pyramids. They harbour signs of ancestry similar to that of other ancient North Africans, as well as of people from the Middle East, researchers report today in Nature. 'It's incredibly exciting and important,' says David Reich, a population geneticist at Harvard Medical School in Boston, Massachusetts, who was not involved in the study. 'We always hoped we would get our first ancient DNA from mummies.' On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today. Numerous labs have tried to extract DNA from ancient Egyptian remains. In 1985, evolutionary geneticist Svante Pääbo reported the first ancient DNA sequences from any human: several thousand DNA letters from a 2,400-year-old Egyptian mummy of a child. But Pääbo, who won a Nobel prize in 2022 for other work, later realized that the sequences were contaminated with modern DNA — possibly his own. A 2017 study generated limited genome data from three Egyptian mummies that lived between 3,600 and 2,000 years ago. The hot North African climate speeds up the breakdown of DNA, and the mummification process might also accelerate it, said Pontus Skoglund, a palaeogeneticist at the Francis Crick Institute in London who co-led the Nature study, at a press briefing. 'Mummified individuals are probably not a great way to preserve DNA.' The remains that Skoglund's team sequenced pre-date widespread mummification: the person was interred instead in a ceramic pot, a sign of high, but not elite, status. The remains were found at an archaeological site called Nuwayrat, 265 kilometres south of Cairo along the Nile river. The teeth and bones were discovered in 1902, when Egypt was under British colonial rule. They were donated to institutions in Liverpool, UK, where they have been ever since, even surviving German bombing during the Second World War. Low expectations Skoglund says his expectations were low when his team extracted DNA from several teeth from the Nuwayrat individual. But two samples contained enough authentic ancient DNA to generate a full genome sequence. Y-chromosome sequences indicated that the remains belonged to a male. The majority of his DNA resembled that of early farmers from the Neolithic period of North Africa around 6,000 years ago. The rest most closely matched people in Mesopotamia, a historical Middle Eastern region that was home to the ancient Sumerian civilization, and was where some of the first writing systems emerged. It's not clear whether this implies a genetic direct link between members of Mesopotamian cultures and people in ancient Egypt — also hinted at by similarities in some cultural artefacts — or whether the man's Mesopotamian ancestry arrived through other unsampled populations, the researchers say. The rest of the ancient Egyptian man's bones revealed more details about his life. Evidence of arthritis and osteoporosis suggest he died at an advanced age for the time, possibly in his sixties. Other signs of wear indicate a life of physical toil, sitting hunched over on hard surfaces. On the basis of this and imagery from other tombs from this period, he might have been a potter, said co-author Joel Irish, a bioarchaeologist at Liverpool John Moores University, at the press briefing. 'The publication of a whole-genome data set of an ancient Egyptian constitutes a significant achievement in the field of molecular Egyptology,' says Yehia Gad, a geneticist at Egypt's National Research Centre in Cairo, who praises the researchers for presenting the provenance of the remains clearly. But he points out that the genome is from one individual and might not fully represent ancient Egypt's gene pool, which was probably a melting pot of different ancestries. For this reason, researchers are eager for more ancient Egyptian genome data — perhaps even from a mummy. Advances in ancient-genomics technology and local capacity — Gad supervises an ancient DNA lab at the National Museum of Egyptian Civilization in Cairo — means it hopefully won't take another 40 years.
